×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
ON DEMAND - Getting Real About Data Sharing for Drug Development and Drug Safety: What COVID-19 is Teaching us About the Possibilities and How to Move From Anomaly to Precedent
Session Chair(s)
Carla Rodriguez-Watson, PhD, MPH
Reagan-Udall Foundation for the FDA, United States
A panel of distinguished leaders in healthcare, consumer advocacy, and regulated industry will discuss how COVID-19 has broken the paradigm for data sharing as it pertains to drug development and drug safety research – and take the audience through an exercise to define shared value to move forward with a renewed commitment to more open data sharing with public health at its core.
Learning Objective : Recognize barriers to data sharing for the purposes of drug safety and pharmacovigilance; Identify shared goals across consumer, health system, government, and industry stakeholders; Outline a platform for the responsible and collaborative engagement in data sharing and linkage for the purpose of drug safety and pharmacovigilance.
Speaker(s)
Panelist
Sarah Greene, MPH
Independent Consultant, United States
Strategic Consultant and Advisor
Panelist
Carlos Garner, PhD
Eli Lilly and Company, United States
Vice-President Global Regulatory Affairs
Panelist
Deven McGraw, JD, LLM, MPH
Invitae, United States
Lead, Data Stewardship and Data Sharing
Have an account?